attention and staff's attention, and the drug i recall he mentioned, and i'll try to say it right, doxirubison, an ovarian cancer drug, that he's prescribed for a long time, an effective drug i'm told. what was the fda's role in interrupting the production of that drug? can you speak to that? >> i can speak to it very generally. there were several companies that produced the drug. one of them was a major supplier also was the same producer for the drug dr. qoh mentioned earlier. some of the issues were the same, facility issues, production delays because of, you know, chronic problems in an aging facility is the best way to summarize. what fda did is we worked with the other two producers to facilitate their ability to increase production. it did take awhile. they were, as i said, these are complex products to make. companies just can't ramp up production over night. >> right. >> but in the meantime, a fourth company came in with a new version of the product, and they helped to make up the supply, so we worked -- we made sure to expedite review of that fourth company's application and any insp

attention and staff's attention, and the drug i recall he mentioned, and i'll try to say it right, doxirubisonan ovarian cancer drug, that he's prescribed for a long time, an effective drug i'm told. what was the fda's role in interrupting the production of that drug? can you speak to that? >> i can speak to it very generally. there were several companies that produced the drug. one of them was a major supplier also was the same producer for the drug dr. qoh mentioned earlier. some of the issues were the same, facility issues, production delays because of, you know, chronic problems in an aging facility is the best way to summarize. what fda did is we worked with the other two producers to facilitate their ability to increase production. it did take awhile. they were, as i said, these are complex products to make. companies just can't ramp up production over night. >> right. >> but in the meantime, a fourth company came in with a new version of the product, and they helped to make up the supply, so we worked -- we made sure to expedite review of that fourth company's application and any inspec